title: [IMPROVING THE EFFICACY OF THERAPY FOR PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY CIRCULATORY FAILURE].
abstract: The effectiveness of drug remaxol inclusion in the scheme of treatment of patients with myocardial infarction on the background of degree III - III acute cardiac insufficiency was evaluated by the analysis of clinical and laboratory data of 126 patients with newly diagnosed acute myocardial infarction including ST-segment elevation on the background of acute cardiac insufficiency. Depending on the regimen, patients were divided into two groups. The first (control) group included 60 patients who received conventional thrombolytic therapy; the second (main) group included 66 patients which, after thrombolytic therapy, received remaxol (single daily intravenous administration, 400 mL at 3 - 4 mL/min rate) with controlled central venous pressure, arterial pressure, and diuresis. The course lasted for 3 - 5 days, depending on the severity of condition. A high efficiency of the treatment regimen including remaxol was established as characterized by more rapid (in comparison to conventional therapy) stabilization of disturbed systemic hemodynamics and recovery of weakened myocardial contractility, decreased risk of cardiac arrhythmias, and relieved hyperhomocysteinemia that, in turn, reduced the risk of complications such as thrombosis and thromboembolism.
authors.forename: V M
authors.initials: VM
authors.lastname: Zhenilo
authors.forename: A Z
authors.initials: AZ
authors.lastname: Avsaragova
authors.forename: Z T
authors.initials: ZT
authors.lastname: Astakhova
mesh_terms: D000368:Aged; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D020138:Hyperhomocysteinemia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012770:Shock, Cardiogenic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013386:Succinates / Q000627:therapeutic use*; D013923:Thromboembolism / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D015912:Thrombolytic Therapy / Q000379:methods; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D005343:Fibrinolytic Agents; C555877:Remaxol; D013386:Succinates